RU2764523C2 - Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора - Google Patents

Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора Download PDF

Info

Publication number
RU2764523C2
RU2764523C2 RU2019114600A RU2019114600A RU2764523C2 RU 2764523 C2 RU2764523 C2 RU 2764523C2 RU 2019114600 A RU2019114600 A RU 2019114600A RU 2019114600 A RU2019114600 A RU 2019114600A RU 2764523 C2 RU2764523 C2 RU 2764523C2
Authority
RU
Russia
Prior art keywords
group
phenyl
substituted
independently selected
hydrogen
Prior art date
Application number
RU2019114600A
Other languages
English (en)
Russian (ru)
Other versions
RU2019114600A3 (enExample
RU2019114600A (ru
Inventor
Ли ЧЖУ
Яндун ХУ
Вэй У
Лигуан ДАЙ
Сяовэй ДУАНЬ
Яньцин ЯН
Инхуэй СУНЬ
Юнсинь ХАНЬ
Юн ПЭН
Фаньшэн КУН
Хун ЛУО
Лин Ян
Хунцзян СЮЙ
Мэн ГУО
Чжаобай ЧЖУН
Шаньчунь ВАН
Original Assignee
Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд.
Центаурус Биофарма Ко., Лтд.
Ляньюньган Жуньчжун Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд., Центаурус Биофарма Ко., Лтд., Ляньюньган Жуньчжун Фармасьютикал Ко., Лтд. filed Critical Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд.
Publication of RU2019114600A publication Critical patent/RU2019114600A/ru
Publication of RU2019114600A3 publication Critical patent/RU2019114600A3/ru
Application granted granted Critical
Publication of RU2764523C2 publication Critical patent/RU2764523C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2019114600A 2016-10-28 2017-10-27 Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора RU2764523C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201610970314.3 2016-10-28
CN201610970314 2016-10-28
CN201710044000 2017-01-21
CN201710044000.5 2017-01-21
PCT/CN2017/108100 WO2018077246A1 (zh) 2016-10-28 2017-10-27 用作神经营养因子酪氨酸激酶受体抑制剂的氨基吡唑并嘧啶化合物

Publications (3)

Publication Number Publication Date
RU2019114600A RU2019114600A (ru) 2020-11-30
RU2019114600A3 RU2019114600A3 (enExample) 2021-02-20
RU2764523C2 true RU2764523C2 (ru) 2022-01-18

Family

ID=62024344

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019114600A RU2764523C2 (ru) 2016-10-28 2017-10-27 Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора

Country Status (15)

Country Link
US (1) US10829492B2 (enExample)
EP (1) EP3533796B1 (enExample)
JP (1) JP7046940B2 (enExample)
KR (1) KR102616249B1 (enExample)
CN (1) CN109890820B (enExample)
AU (1) AU2017348826B2 (enExample)
CA (1) CA3041942C (enExample)
DK (1) DK3533796T3 (enExample)
ES (1) ES2896943T3 (enExample)
HU (1) HUE057733T2 (enExample)
MX (1) MX380283B (enExample)
PL (1) PL3533796T3 (enExample)
PT (1) PT3533796T (enExample)
RU (1) RU2764523C2 (enExample)
WO (1) WO2018077246A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3658148T (pt) * 2017-07-28 2024-08-26 Turning Point Therapeutics Inc Compostos macrocíclicos e utilizações dos mesmos
KR102619444B1 (ko) 2017-08-23 2023-12-29 치아타이 티안큉 파마수티컬 그룹 주식회사 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
TW202033526A (zh) * 2018-12-07 2020-09-16 大陸商貝達藥業股份有限公司 用作酪胺酸激酶抑制劑的化合物、包含其的藥物組合物及其用途
WO2020187291A1 (zh) 2019-03-19 2020-09-24 华中师范大学 吡唑并嘧啶化合物和药物组合物及其应用
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021249450A1 (zh) * 2020-06-11 2021-12-16 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN113563343B (zh) * 2020-07-27 2022-05-24 杭州邦顺制药有限公司 取代的吡唑并[1,5-a]嘧啶化合物及其用途
CN112010860B (zh) * 2020-08-05 2023-03-10 南京纳丁菲医药科技有限公司 苄氧基吡唑并嘧啶化合物和药物组合物及其应用
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
CN113200963A (zh) * 2021-03-31 2021-08-03 广东石油化工学院 N-(吡咯基)-3-吡唑基胺及其制备方法
EP4335441B1 (en) * 2021-05-03 2025-05-28 JBKLAB Co., Ltd. Pharmaceutical composition for preventing, alleviating, or treating cancer, containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7h-pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient
CN117751121A (zh) * 2021-07-30 2024-03-22 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物的晶体
WO2023011616A1 (zh) * 2021-08-06 2023-02-09 正大天晴药业集团股份有限公司 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
CN117088800B (zh) * 2023-08-18 2024-05-28 龙曦宁（上海）医药科技有限公司 一种5-甲基吡咯烷-3-醇盐酸盐的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN104995172A (zh) * 2013-02-19 2015-10-21 小野药品工业株式会社 Trk抑制化合物
RU2584157C2 (ru) * 2009-07-09 2016-05-20 Эррэй Биофарма Инк. ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА КАК ИНГИБИТОРЫ КИНАЗЫ TRK
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10356579A1 (de) * 2003-12-04 2005-07-07 Merck Patent Gmbh Aminderivate
CA2722418C (en) 2008-05-13 2013-09-17 Irm Llc Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
CA2727250A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Bicyclic heterocycles as mek kinase inhibitors
SI2350075T1 (sl) 2008-09-22 2014-06-30 Array Biopharma, Inc. Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji
CN102264736B (zh) * 2008-10-22 2013-08-14 阵列生物制药公司 作为TRK激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013028263A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
EP2970288A1 (en) * 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN104650092B (zh) 2013-11-16 2017-11-10 广东东阳光药业有限公司 取代的杂芳基化合物及其组合物和用途
HUE046727T2 (hu) * 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2584157C2 (ru) * 2009-07-09 2016-05-20 Эррэй Биофарма Инк. ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА КАК ИНГИБИТОРЫ КИНАЗЫ TRK
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN104995172A (zh) * 2013-02-19 2015-10-21 小野药品工业株式会社 Trk抑制化合物
WO2016097869A1 (en) * 2014-12-15 2016-06-23 Cmg Pharmaceutical Co., Ltd. Fused ring heteroaryl compounds and their use as trk inhibitors

Also Published As

Publication number Publication date
PL3533796T3 (pl) 2022-01-17
ES2896943T3 (es) 2022-02-28
DK3533796T3 (da) 2021-11-08
MX2019004847A (es) 2019-08-29
AU2017348826A1 (en) 2019-05-23
MX380283B (es) 2025-03-12
RU2019114600A3 (enExample) 2021-02-20
JP7046940B2 (ja) 2022-04-04
CN109890820A (zh) 2019-06-14
CA3041942C (en) 2023-03-14
US20190352306A1 (en) 2019-11-21
KR102616249B1 (ko) 2023-12-21
BR112019008656A8 (pt) 2022-06-07
JP2019537588A (ja) 2019-12-26
HUE057733T2 (hu) 2022-06-28
CN109890820B (zh) 2020-11-03
PT3533796T (pt) 2021-11-18
RU2019114600A (ru) 2020-11-30
CA3041942A1 (en) 2018-05-03
EP3533796A4 (en) 2020-06-03
EP3533796B1 (en) 2021-09-29
US10829492B2 (en) 2020-11-10
BR112019008656A2 (pt) 2019-07-09
WO2018077246A1 (zh) 2018-05-03
KR20190067913A (ko) 2019-06-17
AU2017348826B2 (en) 2021-12-02
EP3533796A1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
EP3533796B1 (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CN111153901B (zh) 一类含氮稠杂环类shp2抑制剂化合物、制备方法和用途
CN109963842B (zh) 苯并咪唑类化合物激酶抑制剂及其制备方法和应用
KR101813830B1 (ko) 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
JP6165977B2 (ja) ヘテロアリールピリドン及びアザ−ピリドンアミド化合物
ES2857251T3 (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton
KR102619444B1 (ko) 아미노피라졸 및 피리미딘을 함유하는 마크로사이클 및 그의 약학적 조성물 및 용도
CN103582638B (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
WO2020156437A1 (zh) Akt抑制剂
JP2023549187A (ja) 貧血およびがんの処置のためのｖｈｌ阻害剤としての１－（２－（４－シクロプロピル－１ｈ－１，２，３－トリアゾール－１－イル）アセチル）－４－ヒドロキシ－ｎ－（ベンジル）ピロリジンｅ－２－カルボキサミド誘導体
EP4436963A1 (en) Heterobifunctional compounds as hpk1 degraders
RU2779497C2 (ru) Макроцикл, содержащий аминопиразол и пиримидин, и его фармацевтическая композиция и применение
BR112019008656B1 (pt) Composto de aminopirazolopirimidina, composição farmacêutica que compreende o mesmo e uso do dito composto para a profilaxia ou o tratamento de uma doença mediada por receptor de tirosina quinase de fator neurotrófico
HK40002935A (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
HK40002935B (en) Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
CN111377922B (zh) 稠合三环类化合物及其用途
WO2025255442A1 (en) Trim21-targeted compounds and uses thereof
HK40029944B (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40029944A (en) Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use
HK40019194B (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof
HK40019194A (en) Macrocycle containing aminopyrazole and pyrimidine and pharmaceutical composition and use thereof